GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits

GSK has agreed to a settlement exceeding $2 billion to address the remaining liability cases in the United States related to claims that Zantac, its discontinued heartburn medication, is linked to cancer. The pharmaceutical company announced it has reached agreements with ten law firms to resolve approximately 93% of the ongoing Zantac lawsuits, which equates to around 80,000 cases. The settlement is expected to cost the company up to $2.2 billion, marking a significant step in concluding the legal battles tied to the medicine.